Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
Licensed assets enter the clinic
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
Lilly buys in another PI3Kα inhibitor
Scorpion's STX-478 becomes at least the third shot Lilly has taken at PI3Kα.
The gist of GSK's move is to follow Ono
The UK company buys IRDx for $1bn.
Mersana shows that B7-H4 expression matters
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
Zai Lab takes a second punt on MediLink
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
Celcuity goes early with its Pfizer cast-off
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
Biocytogen and PTK7 remain hot
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
Pfizer moves pivotal assets into the front line
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
